Vertical: CNMBase Year: 2025
Market Size (2025)
$166.63M
Projected (2032)
$218.11M
CAGR (2022–2032)
4.6%
Key Players
9+
Market Overview
The Global Resorbable Polymer Market is valued at USD 166.63 Million in 2025, up from USD 139.36 Million in 2022, and is projected to reach USD 218.11 Million by 2032, registering a CAGR of 3.80% over 2026–2032. In absolute terms, the market is expected to add USD 51.48 Million in value between 2025 and 2032. Resorbable polymers are synthetic, medical-grade aliphatic polyesters and related materials that degrade in the body through hydrolysis into metabolisable by-products, eliminating the need for implant-removal surgery and enabling controlled release of active pharmaceutical ingredients. The market covers medical-grade resins and polymer forms used by device and pharmaceutical manufacturers, and is characterised by low volumes, high unit value, stringent quality requirements and long customer-qualification cycles.
Demand is anchored in three end markets: orthopedic fixation devices such as interference screws, suture anchors, pins and craniomaxillofacial plates; drug delivery systems such as microspheres, in-situ forming depots and implants for long-acting injectables; and absorbable sutures, meshes and other surgical products. Growth through 2032 is supported by rising surgical volumes linked to population ageing, an expanding pipeline of long-acting injectable therapies, increasing adoption of minimally invasive and sports medicine procedures, and continuous improvements in polymer engineering that allow suppliers to tune degradation profiles and mechanical properties to specific clinical needs.
Key Findings
By Polymer Type: PLGA is the largest segment with USD 58.32 Million in 2025 (35.0% share), rising to USD 78.93 Million by 2032. PCL is the fastest-growing segment, with a CAGR of 4.69% over 2026–2032.
By Application: Orthopedic Devices and Sutures & Others are jointly the largest segments in 2025, each valued at USD 58.32 Million (35.0% share each). Orthopedic Devices pulls ahead over the forecast period to reach USD 76.95 Million by 2032. Drug Delivery is the fastest-growing application, with a CAGR of 4.51%.
By Region: North America leads the market with USD 66.65 Million in 2025 (40.0% share). Asia Pacific is the fastest-growing region, with a CAGR of 5.28%, and adds USD 18.52 Million between 2025 and 2032, the largest absolute gain of any region.
By Country: The U.S. is the leading country market with USD 57.32 Million in 2025, equal to 34.4% of the global market and 86.0% of North America. India is the fastest-growing country, with a CAGR of 7.61%, followed by China at 6.54% and Mexico at 6.50%.
Segmentation Summary
By polymer type, the market is segmented into PLGA, PLA, PCL and Others. PLGA leads because its lactide-to-glycolide ratio can be adjusted to deliver degradation times from weeks to months, making it the reference polymer for long-acting injectable formulations. PLA, valued at USD 49.99 Million in 2025, remains the material of choice for load-bearing orthopedic fixation, while PCL is gaining share in slow-degrading implants, tissue-engineering scaffolds and blends. The Others segment, which includes polyglycolic acid, polydioxanone and specialty copolymers, accounts for USD 33.33 Million in 2025.
By application, the market is segmented into Orthopedic Devices, Drug Delivery and Sutures & Others. Drug Delivery, valued at USD 49.99 Million in 2025, is set to grow fastest as pharmaceutical companies extend the life cycle of established molecules through depot formulations and develop new long-acting therapies in psychiatry, oncology, endocrinology and pain management. By region, the market covers North America, Europe, Asia Pacific, Latin America and Middle East & Africa, with mature markets accounting for the majority of value and emerging markets delivering the highest growth rates.
Competitive Landscape Summary
The supply side of the market is moderately consolidated. A small group of specialty chemical and life-science companies, led by Evonik Industries, Corbion and Ashland, supply a large proportion of the GMP-grade resorbable resins consumed worldwide. They are complemented by specialist converters, compounders and custom developers such as Zeus, Poly-Med and Foster, and by Asian producers such as Gunze, Samyang Biopharmaceuticals and BMG, which hold strong positions in Japan, South Korea and export markets for absorbable materials. Competition is based on regulatory documentation (drug master files and device master files), lot-to-lot consistency, the breadth of polymer grades and the ability to support customers from early development through commercial supply. Key strategic themes since 2022 include capacity expansions for GMP polymer production, portfolio reshaping, partnerships with drug developers and investment in new formats such as fibers, filaments for additive manufacturing and pre-formed components.
Challenges and Opportunities
The main challenges for market participants are the high cost and long duration of regulatory approval for implantable and drug-delivery products, pricing pressure from hospital procurement programmes and cost-containment policies, the technical difficulty of matching degradation behaviour to healing timelines, and competition from permanent implants and alternative resorbable materials such as magnesium alloys. Sterilisation capacity constraints, including tighter emission controls on ethylene oxide sterilisation in the United States, add further complexity to the supply chain.
Opportunities are concentrated in long-acting injectables, where an expanding pipeline of depot products requires polymers with tightly controlled molecular weight, end-group chemistry and residual-monomer levels; in sports medicine and pediatric orthopedics, where avoiding removal surgery offers clear clinical value; in bioresorbable vascular and peripheral scaffolds; and in high-growth emerging markets, particularly China, India and Mexico, where rising healthcare spending and local device manufacturing are lifting demand.
Future Outlook
The Global Resorbable Polymer Market is expected to grow steadily from USD 174.36 Million in 2026 to USD 218.11 Million in 2032. The composition of demand will shift gradually towards PLGA and PCL, whose combined share rises over the forecast period, and towards Drug Delivery, whose share of the market increases from 30.0% in 2025 to 31.5% in 2032. Regionally, Asia Pacific's share is projected to rise from 25.0% in 2025 to 27.6% in 2032, while North America retains its leading position on the strength of its established device and pharmaceutical industries. Asia Pacific is projected to overtake Europe as the second-largest region in 2031. Suppliers able to combine regulatory depth, application know-how and regional manufacturing presence are best placed to capture this growth.
The Resorbable Polymer Market market is projected to grow at a CAGR of 4.6% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Resorbable polymers, also referred to as bioresorbable or bioabsorbable polymers, are synthetic polymers designed to perform a temporary function in the body and then degrade, primarily by hydrolysis of their ester bonds, into low-molecular-weight products that are metabolised or excreted. The principal chemistries are aliphatic polyesters produced by ring-opening polymerisation of cyclic monomers: poly(lactic acid) or polylactide (PLA, including PLLA, PDLA and PDLLA), poly(lactide-co-glycolide) (PLGA), poly(ε-caprolactone) (PCL), polyglycolide (PGA), polydioxanone (PDO) and their copolymers and blends. Their degradation time ranges from a few weeks for glycolide-rich copolymers to several years for high-molecular-weight PLLA and PCL.
For the purpose of this study, the market includes medical-grade and pharmaceutical-grade resorbable polymers supplied as resins, granules, powders and polymer forms (such as fibers, tubes, films and microparticle-ready grades) for use in orthopedic devices, drug delivery systems, sutures and other medical applications. Market value is measured at the level of polymer sales. The study excludes commodity and packaging-grade PLA and other biodegradable plastics used in consumer and industrial applications, natural resorbable materials such as collagen, gelatin, chitosan and hyaluronic acid, resorbable metals such as magnesium and zinc alloys, and resorbable ceramics such as tricalcium phosphate when sold on their own. The value of finished medical devices and drug products is also excluded.
Scope of the Study
The study analyses the Global Resorbable Polymer Market across two segmentations and five regions, exactly as defined in the underlying market dataset:
By Polymer Type: PLGA, PLA, PCL and Others.
By Application: Orthopedic Devices, Drug Delivery and Sutures & Others.
By Region: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia Pacific), Latin America (Brazil, Argentina, Rest of Latin America) and Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA).
Timeline: historic years 2022–2024, base year 2025 and forecast period 2026–2032, with growth rates expressed as CAGR over 2026–2032.
Unit: all values are presented in USD Million.
Research Objectives
To estimate the size of the Global Resorbable Polymer Market in value terms for the historic period 2022–2024 and the base year 2025, and to forecast it for 2026–2032.
To analyse the market by polymer type (PLGA, PLA, PCL and Others) and identify the chemistries gaining share in device and drug-delivery applications.
To assess demand by application across orthopedic devices, drug delivery, and sutures and other surgical products.
To quantify the market across five regions and their constituent countries, and to identify the fastest-growing geographic markets.
To evaluate the drivers, restraints, opportunities, trends and challenges shaping demand for medical-grade resorbable polymers.
To examine the value chain, competitive forces, regulatory framework and macro-environmental factors affecting suppliers and their customers.
To profile the leading polymer suppliers and analyse their product portfolios, recent developments and strategies.
To provide decision-makers with a reliable basis for investment, capacity-planning and market-entry decisions.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process. It began with the definition of the market and its segmentation, followed by extensive secondary research to build an understanding of polymer chemistries, applications, supply chains and the competitive environment. Primary research with participants across the value chain was then used to validate and refine the findings. Market size was estimated using both top-down and bottom-up approaches, reconciled through data triangulation, and projected over the forecast period using a factor-based model. Each stage included internal quality reviews to ensure consistency between segments, regions and countries.
Secondary Research
Secondary research drew on sources relevant to the medical polymer, medical device and pharmaceutical industries, including:
Industry associations: publications from bodies such as AdvaMed, MedTech Europe, the Society for Biomaterials, the European Society for Biomaterials and the Controlled Release Society.
Government and regulatory bodies: device classification databases, premarket notifications and approvals, and guidance documents from the U.S. Food and Drug Administration, the European Commission and European Medicines Agency, China's National Medical Products Administration, Japan's PMDA, India's CDSCO and other national authorities.
Standards organisations: ISO and ASTM International standards covering resorbable polymer resins, degradation testing and biocompatibility.
Company filings: annual reports, investor presentations, sustainability reports and press releases of polymer suppliers, device manufacturers and pharmaceutical companies.
Trade journals and scientific literature: peer-reviewed journals in biomaterials, controlled release and orthopedics, and trade publications covering medical plastics and drug delivery.
Paid databases: company financial databases, clinical trial registries, trade statistics and proprietary market databases.
Primary Research
Primary research was conducted through in-depth interviews and structured discussions with industry participants on both the supply and demand sides. Supply-side respondents included product managers, business development executives and technical specialists at resorbable polymer manufacturers, monomer suppliers, contract manufacturers and distributors. Demand-side respondents included R&D, procurement and regulatory professionals at orthopedic and surgical device companies, formulation scientists at pharmaceutical and drug-delivery companies, and clinicians and procurement managers in hospitals.
The objectives of primary research were to validate market definitions and segmentation, verify estimates of market size and segment splits, gather insights on pricing, purchasing behaviour and supplier selection criteria, understand regional differences in adoption and regulation, and assess the outlook for new applications and technologies.
Market Size Estimation
Top-down approach: The overall market was estimated by starting from the broader markets for orthopedic fixation devices, absorbable sutures and polymer-based long-acting injectables, and applying the share of value attributable to resorbable polymer inputs. Global totals were then allocated to regions, countries and segments using penetration rates, procedure volumes and product mix.
Bottom-up approach: Revenues attributable to resorbable polymers were estimated for leading suppliers using company disclosures, product portfolios, production capacities and interview inputs, and aggregated to build the market from the supply side. In parallel, demand-side estimates were built from device and drug product volumes multiplied by polymer content and average selling prices.
Data triangulation: The results of the top-down and bottom-up approaches were compared and reconciled. Differences were investigated and resolved through additional secondary research and follow-up discussions with respondents, so that the final estimates are consistent across segments, regions and countries.
Forecasting Methodology
Forecasts were developed using a factor-based model that combines historic growth trends with forward-looking assessments of demand drivers and constraints. Factors considered include demographic trends and surgical procedure volumes, healthcare expenditure, approval pipelines for long-acting injectables and resorbable devices, adoption rates of resorbable versus permanent implants, regulatory changes, pricing trends, raw material costs and regional manufacturing developments. Each factor was weighted according to its expected impact in each forecast period, and the results were validated through primary interviews.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024.
Base year: 2025.
Forecast period: 2026–2032, with CAGR calculated over 2026–2032.
Currency: all values are presented in USD Million.
Assumptions and Limitations
Market values reflect sales of resorbable polymers at the supplier level and do not include the value added by device or drug manufacturers.
Exchange rates are assumed to remain broadly stable over the forecast period, and values are expressed in nominal terms.
The regulatory environment is assumed to evolve along currently announced timelines, with no major disruptive changes to the approval pathways for resorbable devices or long-acting injectables.
Several suppliers do not report revenues for their resorbable polymer businesses separately, so supply-side estimates rely partly on modelled values and expert input.
Unforeseen events such as major product recalls, supply disruptions or macroeconomic shocks could cause actual results to differ from the forecasts.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Resorbable Polymer Market is moderately consolidated. A small number of specialty chemical companies, led by Evonik Industries, Corbion and Ashland, account for a large share of GMP-grade resorbable polymer supply for both medical devices and drug delivery. These leaders benefit from decades of experience, multiple qualified grades referenced in customers' regulatory filings, and global technical and regulatory support. They are complemented by specialist converters and compounders, such as Zeus, Poly-Med and Foster, which add value by turning polymers into extrusions, fibers, textiles and compounds, and by Asian producers that serve fast-growing domestic markets and increasingly compete internationally.
Competition is based primarily on product quality and consistency, regulatory documentation, breadth of polymer chemistries, application and formulation support, and security of supply rather than on price. Because a polymer grade, once specified in an approved device or drug, is rarely changed, suppliers compete intensely to be selected at the development stage. Recent competitive activity has focused on GMP capacity expansion, new product forms for additive manufacturing and implants, high-purity grades for long-acting injectables, distribution partnerships and portfolio restructuring.
Key Player Positioning
Based on product portfolio breadth, regulatory depth, geographic reach and installed customer base, the profiled companies can be grouped into leaders, challengers and niche players.
Leaders: Evonik Industries AG, Corbion N.V., Ashland Inc.. These companies offer the broadest ranges of GMP-grade lactide, glycolide and caprolactone polymers for devices and drug delivery, with global customer bases and extensive regulatory documentation.
Challengers: Zeus Company LLC, Gunze Limited, Samyang Biopharmaceuticals Corp.. These companies hold strong positions in specific product forms, applications or regions and are investing to expand their presence.
Niche players: Poly-Med, Incorporated, Foster Corporation (GEON Performance Solutions), BMG Incorporated. These companies focus on specialised chemistries, custom development, compounding or regional markets.
Evonik Industries AG
Overview: Evonik Industries AG is a German specialty chemicals company headquartered in Essen. Since April 2025 it has reported through two segments, Custom Solutions and Advanced Technologies. Its Health Care business line, part of Custom Solutions, supplies pharmaceutical and medical-device companies with excipients, drug-delivery technologies and contract development and manufacturing services, and is one of the world's largest producers of medical-grade resorbable polymers.
Latest reported revenue: Group sales of EUR 14,069 million in FY2025 (FY2024: EUR 15,157 million).
Relevant products: RESOMER bioresorbable polymers for medical devices, produced in Darmstadt, Germany and Birmingham, Alabama, USA under ISO 13485 and GMP, covering PLLA, PDLLA, PLGA, PLDLLA, PCL, PGA, PDO, glycolide and lactide copolymers with caprolactone and trimethylene carbonate, PLA-PEG block copolymers and composites with hydroxyapatite or β-TCP. Product forms include RESOMER Select custom polymers, RESOMER PrintPowder, filaments, micronised powders, tubes, films and fibers. For drug delivery, RESOMER and LACTEL PLGA and PLA excipients are offered for parenteral controlled release, including low-metal and sterile grades.
Key developments: Apr 2022: Realigned its Health Care business into three product lines, including Drug Delivery & Products, which includes RESOMER polymers; Mar 2023: Entered a collaboration with BellaSeno to commercialise 3D-printed resorbable bone-regeneration scaffolds made from RESOMER polymers; Apr 2024: Expanded capacity in Darmstadt for customised RESOMER powder biomaterials using solvent-free micronisation; Jul 2025: Appointed IMCD as exclusive European distributor for RESOMER medical-device polymers.
Strategy: Evonik is moving from excipient supply towards system solutions that combine polymers, formulation expertise and CDMO services. In medical devices it emphasises customised, processing-ready formats such as powders and filaments for 3D printing, and it is extending market reach through distribution partners.
Corbion N.V.
Overview: Corbion N.V. is a Dutch company with origins in CSM, operating in food ingredients, algae-based nutrition and biomaterials. Its Health & Nutrition segment includes the Biomaterials business, which produces PURASORB medical-grade polymers and biomedical monomers based on lactide, glycolide and caprolactone, drawing on more than four decades of experience in biomaterials.
Latest reported revenue: Sales of EUR 1,267.4 million from continued operations in FY2025 (FY2024: EUR 1,288.1 million).
Relevant products: PURASORB polymers for medical devices and drug delivery, including PLLA, PDLA, PDLLA, PGA and PCL homopolymers and L/D-lactide, L/DL-lactide, PLGA, L-lactide/caprolactone and PEG copolymers, manufactured to GMP and ICH Q7 requirements, together with custom R&D grades and high-purity lactide and glycolide monomers.
Key developments: Nov 2025: Launched its BRIGHT 2030 strategy, naming growth in biomedical polymers as a strategic priority.
Strategy: Under its BRIGHT 2030 strategy launched in November 2025, Corbion has named growth in biomedical polymers as a strategic priority, while reviewing ownership of its industrial PLA bioplastics activities to concentrate on higher-value healthcare applications. Drug delivery, orthopedics and aesthetics are its main demand drivers.
Ashland Inc.
Overview: Ashland Inc. is a U.S. specialty additives and ingredients company headquartered in Wilmington, Delaware, with segments in Life Sciences, Personal Care, Specialty Additives and Intermediates. Its Viatel bioresorbable polymers are part of the Life Sciences injectables business and are manufactured in Mullingar, Ireland.
Latest reported revenue: Sales of USD 1,824 million in FY2025 (year ended 30 September 2025), including USD 641 million from Life Sciences.
Relevant products: Viatel bioresorbable polymers, comprising more than 70 GMP grades of lactide, glycolide and caprolactone homopolymers and copolymers, Viatel Ultrapure high-purity grades with very low residual monomer for long-acting injectables and implants, high-molecular-weight grades for medical devices and aesthetics, and custom polymers.
Key developments: Oct 2023: Launched Viatel Ultrapure high-purity bioresorbable polymers for long-acting injectables and implants; Aug 2024: Completed a second expansion of Viatel manufacturing and its R&D laboratory in Mullingar, Ireland; Jun 2025: Expanded the Viatel range with high-molecular-weight grades for dental and orthopedic implants, tissue engineering and dermal fillers.
Strategy: Ashland is reshaping its portfolio towards higher-value pharmaceutical businesses, with injectables identified as a growth business line. Viatel is positioned on purity, customisation and formulation support for long-acting injectables, with an expanding offering for implants, tissue engineering and aesthetics.
Zeus Company LLC
Overview: Zeus Company LLC, founded in 1966 and headquartered in Orangeburg, South Carolina, USA, is a polymer extrusion and component manufacturer for medical devices, with operations in the United States, Ireland and China. The company was acquired by EQT Private Equity in a transaction completed in February 2024.
Latest reported revenue: Privately held; revenue is not publicly disclosed.
Relevant products: Absorv bioabsorbable extrusions in PLLA, PGA, PCL, PDO and other absorbable polyesters, supplied as precision and expanded tubing, monofilament, tape, rod stock, films, profiles and compounded pellets, and Absorv XSE oriented tubing in PLLA, PLC and PLGA for bioresorbable vascular scaffolds.
Key developments: Sep 2023: Launched Absorv XSE next-generation oriented tubing for bioresorbable vascular scaffolds; Feb 2024: Acquisition of Zeus by EQT Private Equity completed.
Strategy: Zeus positions Absorv as a platform that allows device manufacturers to replace permanent metal implants, particularly vascular scaffolds, offering tunable mechanical and absorption profiles supported by dedicated engineering teams.
Poly-Med, Incorporated
Overview: Poly-Med, Incorporated, founded in 1993 and headquartered in Anderson, South Carolina, USA, is a privately held, vertically integrated developer and manufacturer of bioresorbable polymers and devices. It synthesises absorbable polymers and converts them into fibers, yarns, films, textiles, electrospun constructs and 3D-printed parts under an ISO 13485 quality system.
Latest reported revenue: Privately held; revenue is not publicly disclosed.
Relevant products: Proprietary absorbable polymer families including Max-Prene, Dioxaprene, Glycoprene, Lactoprene and Caproprene, based on segmented and block copolymers of glycolide, lactide, caprolactone, trimethylene carbonate and p-dioxanone, together with GMP 3D-printing filaments, an absorbable photopolymer resin, absorbable sutures, yarns and meshes, and contract manufacturing of implants.
Strategy: Poly-Med differentiates through proprietary copolymer chemistries and vertical integration from polymer synthesis to finished devices, helping device companies shorten development timelines, and is expanding into additive manufacturing materials.
Foster Corporation (GEON Performance Solutions)
Overview: Foster Corporation, founded in 1989 and headquartered in Putnam, Connecticut, USA, is a custom compounder of medical polymers, including implantable and bioresorbable materials, operating under an ISO 13485:2016 quality system. It was acquired by GEON Performance Solutions, a portfolio company of SK Capital Partners, in January 2025 and now serves as GEON's medical brand.
Latest reported revenue: Privately held; revenue is not publicly disclosed.
Relevant products: Bioresorbable compounds based on PLA, PLLA, PGA, PLGA, PCL and their alloys, including osteoconductive grades with β-TCP or hydroxyapatite and radiopaque grades, compounded in cleanroom conditions and supplied as pellets or directly extruded rods, fibers, tubing and films.
Key developments: Jan 2025: Acquired by GEON Performance Solutions, a portfolio company of SK Capital Partners; Jan 2026: Formerra became preferred European distributor for Foster medical compounds.
Strategy: Foster acts as a formulation partner for Class III implant applications, adding functionality such as radiopacity and osteoconductivity to resorbable polymers, and is leveraging GEON's resources and expanded distribution to scale.
Gunze Limited
Overview: Gunze Limited, founded in 1896 and headquartered in Japan, is a diversified manufacturer of apparel, plastic films, engineering plastics and medical devices. Its medical business, a separate reporting segment since FY2023, began marketing bioabsorbable sutures in Japan in 1986 and now sells bioabsorbable medical products in more than 35 countries.
Latest reported revenue: Consolidated net sales of JPY 130,918 million for the fiscal year ended 31 March 2026.
Relevant products: Bioabsorbable products based on PGA, PLLA and lactide-caprolactone copolymers, including NEOVEIL PGA reinforcement felt, GRAND FIX PLLA bone-fixation systems, SEAMDURA dural substitute and absorbable monofilament sutures, alongside collagen and gelatin-based products.
Key developments: Feb 2022: Launched the TENALEAF absorbable adhesion barrier in Japan; May 2023: Announced a JPY 1.7 billion expansion of its main medical plant in Ayabe and established medical as a separate business segment; Oct 2023: Announced investment of about JPY 3.5 billion in a third medical plant in Ayabe and expansion of R&D facilities; Mar 2025: Completed a new medical R&D facility in Ayabe, Kyoto, opened in April 2025.
Strategy: Under its VISION 2030 plan, Gunze treats its medical business as a growth pillar and is investing in production capacity and R&D in Ayabe, Kyoto, to strengthen its leading positions in absorbable reinforcement materials and bone fixation and to grow exports.
BMG Incorporated
Overview: BMG Incorporated, founded in 1983 and headquartered in Kyoto, Japan, is a biomaterials company that grew out of research collaboration with Kyoto University. It develops and manufactures medical-grade biodegradable absorbable polymers, absorbable medical devices and cell-preservation solutions, and reports that it developed Japan's first medical bioabsorbable polymer for surgical sutures.
Latest reported revenue: Privately held; revenue is not publicly disclosed.
Relevant products: BioDegmer medical bioabsorbable polymers, including glycolide/DL-lactide copolymers for periodontal regeneration membranes, artificial dura and adhesion barriers, BioDegmer 3D-printing filament, and development-stage high-modulus PLLA materials for bone fixation.
Strategy: BMG operates as an R&D-driven niche supplier of custom absorbable polymers, partnering with strategic corporate investors to commercialise new materials and devices.
Samyang Biopharmaceuticals Corp.
Overview: Samyang Biopharmaceuticals Corp. (Samyang Biopharm) is a South Korean biopharmaceutical and medical-device company that was spun off from Samyang Holdings with effect from 1 November 2025 and listed on the KOSPI in November 2025. It developed Korea's first synthetic absorbable PGA suture and is a major global supplier of biodegradable suture yarn to device manufacturers, alongside businesses in biodegradable aesthetic products, polymeric drug delivery and gene-delivery platforms.
Latest reported revenue: Revenue of KRW 138.3 billion in FY2024 for the biopharmaceutical business, reported as a division of Samyang Holdings; as a standalone company, revenue of KRW 28.6 billion for the period from 1 November to 31 December 2025.
Relevant products: Absorbable suture yarns based on PGA and glycolide copolymers supplied to suture manufacturers worldwide, the MONOFIX knotless wound-closure device made of poly(glycolide-co-ε-caprolactone), the PCL-based Lafullen dermal filler and Croquis thread-lift products, and polymeric micelle drug-delivery technology based on biodegradable mPEG-PDLLA copolymer.
Key developments: Aug 2022: Received U.S. FDA 510(k) clearance for the MONOFIX PGCL knotless wound-closure device; Jun 2023: Opened an absorbable suture plant in Gödöllő, Hungary, its first manufacturing site in Europe; Jun 2023: Signed an agreement with Hangzhou Yxintent for the clinical development, approval and distribution of the Lafullen PCL-based filler in China; Nov 2025: Completed its spin-off from Samyang Holdings and listed on the KOSPI.
Threat of New Entrants: Low
GMP manufacturing, cleanroom processing and analytical infrastructure require significant capital investment and specialised expertise.
Customers require regulatory documentation, long-term stability data and proven lot-to-lot consistency, which take years to build.
Polymer grades are locked into customers’ regulatory filings, so new entrants must wait for new programmes rather than displace incumbents.
Bargaining Power of Suppliers: Medium
High-purity lactide, glycolide and caprolactone are available from a limited number of producers, giving them some pricing influence.
Several leading polymer manufacturers are vertically integrated into monomer production, reducing their dependence on external suppliers.
Raw material costs represent a modest share of the value of medical-grade polymers, limiting the effect of supplier pricing on margins.
Bargaining Power of Buyers: Medium
Large orthopedic, surgical and pharmaceutical companies purchase significant volumes and negotiate long-term contracts.
Switching suppliers requires requalification and, in many cases, regulatory submissions, which significantly reduces buyer leverage once a product is approved.
Buyers have greater leverage at the development stage, when multiple suppliers can compete for new programmes.
Threat of Substitutes: Medium
Permanent implants made from titanium, stainless steel and PEEK remain the standard of care in many high-load orthopedic applications.
Resorbable magnesium alloys, natural polymers such as collagen and hyaluronic acid, and non-polymeric drug delivery technologies compete in specific applications.
The clinical benefit of avoiding removal surgery and the established track record of resorbable polyesters limit substitution in core uses.
Intensity of Competitive Rivalry: Medium
A small number of established suppliers compete for a market in which customer relationships are long-lasting.
Competition focuses on technical service, regulatory support, product range and supply security rather than price alone.
Asian producers are expanding their presence, increasing competition in standard grades and in regional markets.
Threat of New Entrants: Low; Capital, GMP, regulatory documentation and qualification barriers.
Bargaining Power of Suppliers: Medium; Concentrated high-purity monomer supply, offset by vertical integration.
Bargaining Power of Buyers: Medium; Large customers, but high switching costs once products are approved.
Threat of Substitutes: Medium; Permanent implants, resorbable metals and natural polymers in selected uses.
Intensity of Competitive Rivalry: Medium; Few established suppliers competing on service, quality and supply security.
Market estimates by geography (2032)
InsightNorth America leads with $83.43M by 2032, while Asia Pacific is projected to grow fastest at a 6.3% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $57.00M | $71.98M | $83.43M | 3.9% | 38% |
| Europe | $40.18M | $50.32M | $58.02M | 3.7% | 27% |
| Asia Pacific | $32.56M | $46.84M | $60.18M | 6.3% | 28% |
| Latin America | $5.57M | $7.47M | $9.49M | 5.5% | 4% |
| Middle East & Africa | $4.06M | $5.57M | $7.00M | 5.6% | 3% |
| Total | $139.36M | $182.19M | $218.11M | 4.6% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$218.11M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| PLGA | $78.93M | 5.1% | 36% |
| PLA | $62.38M | 3.8% | 29% |
| Others | $42.10M | 4.1% | 19% |
| PCL | $34.70M | 5.5% | 16% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Resorbable Polymer Market covering market dynamics, competitive landscape, and strategic outlook.
The Resorbable Polymer Market market is projected to reach $218.11M by 2032, growing at 4.6% CAGR. The PLGA segment holds the largest share.
The Global Resorbable Polymer Market is shaped by the interaction of healthcare demand, pharmaceutical innovation, regulation and materials science. Demand for resorbable polymers is derived from the device and drug products in which they are used, so market growth depends on procedure volumes, product approvals and the rate at which clinicians and manufacturers substitute resorbable solutions for permanent implants or conventional dosage forms. This chapter analyses the factors that promote and inhibit growth over 2026–2032. The impact scores in the growth factor analysis that follows are analyst assessments based on secondary research and interviews with industry participants, rated on a scale of 1 (minimal impact) to 10 (very strong impact).
Growing Pipeline of Long-Acting Injectables and Depot Formulations
Polymer-based long-acting injectables are the most important growth engine for resorbable polymers. PLGA and PLA microspheres, implants and in-situ forming depots allow a single injection to release a drug over weeks or months, improving adherence in chronic conditions such as schizophrenia, opioid use disorder, prostate cancer, diabetes and osteoarthritis pain. Established products such as leuprolide, octreotide, risperidone and triamcinolone depot formulations have demonstrated the commercial value of this approach, and pharmaceutical companies increasingly use long-acting formats for life-cycle management of off-patent molecules and for new chemical entities. New approvals continue: in January 2023, the U.S. FDA approved a PLGA microsphere-based risperidone injectable administered every two weeks, and generic versions of established PLGA depot products, including risperidone and octreotide microspheres, received U.S. approval in 2025. The FDA has also issued, and in August 2026 revised, product-specific guidance for generic PLGA-based depots such as leuprolide and octreotide that requires detailed characterisation of the polymer, encouraging generic entrants that need qualified polymer supply. Because each formulation is tied to a specific polymer grade that is locked into the regulatory filing, every approved product creates a multi-year, high-value demand stream for the polymer supplier. This dynamic underpins the 4.51% CAGR of the Drug Delivery segment and the 4.31% CAGR of PLGA over 2026–2032, and is driving suppliers to invest in GMP capacity, analytical capabilities and formulation development services.
Rising Surgical Volumes Driven by Ageing Populations
The global population aged 65 and over is growing faster than any other age group, and older patients undergo a disproportionate share of orthopedic, trauma, spine, dental and general surgical procedures. Higher incidence of osteoporosis-related fractures, degenerative joint disease and soft-tissue injuries increases demand for fixation devices, while growth in general surgery drives consumption of absorbable sutures, meshes and haemostatic products. At the same time, the population of younger, active patients undergoing ligament reconstruction and other sports medicine procedures continues to expand. In emerging economies, improving access to surgical care and the expansion of hospital infrastructure are adding to procedure volumes. These trends support stable underlying demand for resorbable polymers in Orthopedic Devices, which is projected to grow from USD 58.32 Million in 2025 to USD 76.95 Million by 2032, and in Sutures & Others, which reaches USD 72.52 Million by 2032.
Clinical Preference for Implants that Eliminate Removal Surgery
Resorbable implants transfer load gradually back to healing bone and tissue, avoid long-term stress shielding, do not interfere with post-operative imaging, and remove the need for a second operation to retrieve hardware. These advantages are particularly valuable in pediatric orthopedics, craniomaxillofacial surgery, foot and ankle surgery and sports medicine, where interference screws and suture anchors made from PLLA, PLDLA and composites with β-tricalcium phosphate or hydroxyapatite are widely used. Removal surgeries carry additional cost, infection risk and patient inconvenience, so payers and hospitals have an incentive to adopt resorbable alternatives where clinical evidence supports equivalent outcomes. The approval of resorbable scaffolds for new indications, such as the everolimus-eluting resorbable scaffold based on polylactic acid that the U.S. FDA approved in April 2024 for arterial disease below the knee, shows that the clinical rationale for resorbable implants is extending beyond orthopedics into cardiovascular and peripheral vascular care.
Advances in Polymer Engineering and Manufacturing Technologies
Polymer suppliers have made significant progress in controlling molecular weight distribution, inherent viscosity, end-group chemistry, copolymer sequence and residual monomer and solvent content. These capabilities allow device and drug developers to specify polymers with reproducible degradation profiles and mechanical properties. New product forms, including medical-grade filaments and powders for additive manufacturing, electrospun fibers, braided and monofilament yarns, and pre-formed tubes and films, are lowering the barriers for device developers and opening new applications such as patient-specific implants, tissue-engineering scaffolds and resorbable meshes. Composite materials combining resorbable polymers with bioactive ceramics are improving osteoconductivity in orthopedic applications. These innovations support premium pricing and are a key factor behind the 4.69% CAGR of the PCL segment, which benefits from its slow degradation and suitability for 3D printing and blending.
Generic and Next-Generation Long-Acting Injectables
As patents on established depot products expire, generic and complex-generic developers are entering the market, and each needs a reliable source of polymer that matches the reference product's characteristics. In parallel, developers of new long-acting formulations for psychiatric disorders, addiction, HIV prevention, ophthalmology and hormone therapies are seeking polymers with tailored release profiles. Suppliers that offer custom synthesis, analytical characterisation and regulatory support can secure long-term supply positions in these programmes.
Expansion in Emerging Markets
Asia Pacific, Latin America and the Middle East & Africa are the fastest-growing regions, with CAGRs of 5.28%, 5.05% and 4.81% respectively over 2026–2032. Rising healthcare expenditure, growing middle-class populations, the expansion of private hospital networks and policies supporting domestic medical device and pharmaceutical manufacturing are creating new demand. India, China and Mexico, with CAGRs of 7.61%, 6.54% and 6.50%, offer particularly attractive opportunities for suppliers prepared to invest in local technical support, regulatory registration and distribution.
Additive Manufacturing, Tissue Engineering and Vascular Applications
Additive manufacturing enables patient-specific resorbable implants for craniomaxillofacial reconstruction, bone-void filling and soft-tissue support, while tissue-engineering research is creating demand for scaffolds that degrade as new tissue forms. Bioresorbable vascular scaffolds, peripheral stents and drug-eluting coatings represent further opportunities following new approvals. These applications favour polymers with precise and reproducible properties and offer higher value per kilogram than conventional uses.
Stringent and Costly Regulatory Pathways
Resorbable implants and drug-delivery products are subject to some of the most demanding regulatory requirements in healthcare. In the European Union, implantable devices that are wholly or mainly absorbed are classified as Class III under the Medical Device Regulation, requiring extensive clinical evidence and notified body review. In the United States, many resorbable implants require premarket approval or substantial-equivalence data supported by degradation, biocompatibility and mechanical testing over the full resorption period. For drug products, any change in the polymer grade or supplier can trigger new bioequivalence or stability studies. These requirements increase development costs and timelines for device and pharmaceutical customers, slowing the introduction of new products and limiting the number of small companies able to bring resorbable products to market.
Technical Limitations and Competition from Alternative Materials
Resorbable polymers have lower strength and stiffness than titanium, stainless steel and PEEK, which limits their use in high-load applications. Degradation products can cause local acidity and inflammatory reactions in some patients, and matching degradation rates to healing times remains technically challenging. Clinical setbacks, such as the withdrawal of the first-generation bioresorbable coronary scaffold in 2017, have made some clinicians cautious. At the same time, resorbable magnesium alloys, natural polymers such as collagen and hyaluronic acid, and improved permanent implants compete for the same applications, constraining the share of procedures in which synthetic resorbable polymers are used.
Pricing Pressure from Procurement Reforms
Hospital group purchasing organisations in the United States, tender-based procurement in Europe and volume-based procurement programmes for orthopedic implants in China have put sustained downward pressure on device prices. Device manufacturers respond by seeking cost reductions from their suppliers, including polymer producers. Although polymer costs represent a small fraction of the finished device price, procurement reforms reduce the premium that resorbable products can command over permanent alternatives and can slow their adoption in price-sensitive markets.
Challenge: Sterilisation and Supply Chain Constraints
Resorbable polymers are sensitive to heat and moisture and are typically sterilised using ethylene oxide or radiation. Stricter emission standards for ethylene oxide sterilisers in the United States, finalised in 2024, and limited sterilisation capacity in several regions add cost and lead time. Supply chains for high-purity lactide, glycolide and caprolactone monomers are concentrated among a small number of producers, creating potential vulnerability to disruption.
Challenge: Demonstrating Long-Term Clinical Value
Payers and clinicians increasingly demand long-term clinical and health-economic evidence before adopting new resorbable products. Generating this evidence requires multi-year studies that track performance through the full resorption period, which can delay adoption and requires sustained investment by device manufacturers and their polymer partners.
Trend: Supplier Investment in GMP Capacity and Services
Leading suppliers are expanding GMP polymer production, cleanroom processing and analytical laboratories, and are bundling polymer supply with formulation, process development and contract manufacturing services. This shift from product sales to integrated solutions increases customer loyalty and raises entry barriers for smaller competitors.
Trend: Composite and Hybrid Materials
Device developers are increasingly combining resorbable polymers with ceramics, bioactive glasses and drugs to create implants that both support healing and actively promote bone growth or prevent infection. Drug-eluting resorbable implants blur the boundary between the Orthopedic Devices and Drug Delivery segments and create new specification requirements for polymer suppliers.
The value chain of the Global Resorbable Polymer Market extends from monomer production through polymer synthesis and conversion to device and drug manufacturers and, ultimately, hospitals and patients. Value is concentrated in the polymer manufacturing stage, where purification, process control and regulatory documentation command high margins.
Raw materials and inputs: Lactic acid, produced mainly by fermentation of sugars or starch, is converted into lactide, while glycolic acid is converted into glycolide. ε-Caprolactone and p-dioxanone are produced through petrochemical routes. Polymerisation catalysts, typically tin(II) 2-ethylhexanoate, and initiators complete the input set. Monomers for medical use must meet very high purity specifications, and supply is concentrated among a small number of qualified producers.
Polymer manufacturing: Resorbable polymers are produced by ring-opening polymerisation under tightly controlled conditions, followed by purification to remove residual monomer, catalyst and solvent. Medical and pharmaceutical grades are manufactured under GMP or ISO 13485 quality systems, with extensive analytical characterisation and regulatory documentation such as drug master files and device master files.
Conversion, distribution and channels: Polymers are supplied as resins, granules or powders, or converted into fibers, filaments, tubes, films and microparticle-ready grades by the polymer producer or by specialist converters. Sales are predominantly direct to device and pharmaceutical manufacturers under long-term supply agreements, while research quantities are sold through catalogues and distributors.
End users: Orthopedic and surgical device manufacturers, pharmaceutical and drug-delivery companies, contract development and manufacturing organisations, and academic and clinical research institutions use the polymers to produce implants, sutures and long-acting formulations that are ultimately used in hospitals, ambulatory surgery centres and clinics.
Resorbable polymers are not usually approved as stand-alone products. Instead, they are regulated as components of medical devices or as excipients in drug products, and suppliers support their customers’ regulatory submissions through master files and technical documentation. Key regulations and standards by region are summarised below.
North America
United States: The Food and Drug Administration regulates resorbable devices under the Federal Food, Drug, and Cosmetic Act. Absorbable sutures are classified under 21 CFR Part 878, including 21 CFR 878.4493 for absorbable poly(glycolide/L-lactide) surgical sutures and 21 CFR 878.4840 for absorbable polydioxanone surgical sutures, while many resorbable implants require 510(k) clearance or premarket approval. Device manufacturers must comply with the Quality Management System Regulation under 21 CFR Part 820, which incorporates ISO 13485 and took effect in February 2026. Polymer-based drug products are approved through new drug applications and abbreviated new drug applications, and polymer suppliers file Type IV or Type V drug master files and device master files.
Canada: Health Canada regulates devices under the Medical Devices Regulations (SOR/98-282), with resorbable implants generally in higher risk classes requiring licence applications, and requires quality management systems certified under the Medical Device Single Audit Program.
Europe
European Union: Regulation (EU) 2017/745 on medical devices (MDR) classifies implantable devices that are wholly or mainly absorbed as Class III, requiring notified body assessment and clinical evidence. Regulation (EU) 2023/607 extended the transition period for legacy devices to 31 December 2027 for Class III and implantable Class IIb devices and to 31 December 2028 for other classes, subject to conditions. Drug products containing resorbable polymers are authorised under Directive 2001/83/EC through the European Medicines Agency or national authorities.
United Kingdom: The Medicines and Healthcare products Regulatory Agency regulates devices under the UK Medical Devices Regulations 2002, with CE-marked devices accepted in Great Britain for a transitional period.
Asia Pacific
China: The National Medical Products Administration regulates devices under the Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739), with implantable resorbable devices typically classified as Class III. Volume-based procurement programmes for orthopedic implants, covering trauma, joint and spine products, have substantially reduced implant prices.
Japan: The Pharmaceuticals and Medical Devices Agency reviews devices and drugs under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act).
India: The Central Drugs Standard Control Organisation regulates devices under the Medical Devices Rules, 2017, with licensing requirements for Class C and Class D devices in force since 1 October 2023.
Latin America and Middle East & Africa
Brazil: ANVISA regulates medical devices under RDC No. 751/2022, which classifies devices by risk and requires registration for higher-risk implants.
Saudi Arabia and the UAE: The Saudi Food and Drug Authority and the UAE Ministry of Health and Prevention regulate devices through marketing authorisation schemes that draw on approvals from reference regulators.
International Standards
ISO 10993 series: Biological evaluation of medical devices, including ISO 10993-1, revised in 2025, on the evaluation of biological safety within a risk management process.
ISO 13485: Quality management systems for medical devices.
ISO 13781: In vitro degradation testing of poly(lactide)-based homopolymers, copolymers and blends for implants for surgery.
ASTM F1925 and ASTM F2579: Specifications for semi-crystalline poly(lactide) resins and amorphous poly(lactide) and poly(lactide-co-glycolide) resins for surgical implants.
ASTM F1635: In vitro degradation testing of hydrolytically degradable polymer resins and fabricated forms for surgical implants.
Feb 2022: Gunze Limited; Product Launch; Launched the TENALEAF absorbable adhesion barrier in Japan.
Apr 2022: Evonik Industries AG; Restructuring; Realigned its Health Care business into three product lines, including Drug Delivery & Products, which includes RESOMER polymers.
Aug 2022: Samyang Biopharmaceuticals Corp.; Regulatory Approval; Received U.S. FDA 510(k) clearance for the MONOFIX PGCL knotless wound-closure device.
Mar 2023: Evonik Industries AG; Partnership; Entered a collaboration with BellaSeno to commercialise 3D-printed resorbable bone-regeneration scaffolds made from RESOMER polymers.
May 2023: Gunze Limited; Expansion; Announced a JPY 1.7 billion expansion of its main medical plant in Ayabe and established medical as a separate business segment.
Jun 2023: Samyang Biopharmaceuticals Corp.; Expansion; Opened an absorbable suture plant in Gödöllő, Hungary, its first manufacturing site in Europe.
Jun 2023: Samyang Biopharmaceuticals Corp.; Partnership; Signed an agreement with Hangzhou Yxintent for the clinical development, approval and distribution of the Lafullen PCL-based filler in China.
Sep 2023: Zeus Company LLC; Product Launch; Launched Absorv XSE next-generation oriented tubing for bioresorbable vascular scaffolds.
Oct 2023: Ashland Inc.; Product Launch; Launched Viatel Ultrapure high-purity bioresorbable polymers for long-acting injectables and implants.
Oct 2023: Gunze Limited; Expansion; Announced investment of about JPY 3.5 billion in a third medical plant in Ayabe and expansion of R&D facilities.
Feb 2024: Zeus Company LLC; Acquisition; Acquisition of Zeus by EQT Private Equity completed.
Apr 2024: Evonik Industries AG; Expansion; Expanded capacity in Darmstadt for customised RESOMER powder biomaterials using solvent-free micronisation.
Aug 2024: Ashland Inc.; Expansion; Completed a second expansion of Viatel manufacturing and its R&D laboratory in Mullingar, Ireland.
Jan 2025: Foster Corporation; Acquisition; Acquired by GEON Performance Solutions, a portfolio company of SK Capital Partners.
Mar 2025: Gunze Limited; Expansion; Completed a new medical R&D facility in Ayabe, Kyoto, opened in April 2025.
Jun 2025: Ashland Inc.; Product Launch; Expanded the Viatel range with high-molecular-weight grades for dental and orthopedic implants, tissue engineering and dermal fillers.
Jul 2025: Evonik Industries AG; Partnership; Appointed IMCD as exclusive European distributor for RESOMER medical-device polymers.
Nov 2025: Corbion N.V.; Strategy; Launched its BRIGHT 2030 strategy, naming growth in biomedical polymers as a strategic priority.
Nov 2025: Samyang Biopharmaceuticals Corp.; Restructuring; Completed its spin-off from Samyang Holdings and listed on the KOSPI.
Jan 2026: Foster Corporation; Partnership; Formerra became preferred European distributor for Foster medical compounds.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 28 companies operating in the Resorbable Polymer Market market, including revenue, employee count, and market positioning where available.
Showing 28 of 28 companies
Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix | Revenue type | Characterisation | Evidence | |---|---|---| | Product sales | Dominant (estimated well above 90% of revenue; exact split not publicly disclosed) | Manufactured coatings, sealants, admixtures and similar products sold through retail, distribution and direct channels | | Installation and services | Material within CPG and PCG; not separately disclosed | WTI/WTC roofing services, turnkey general contracting, TremCare maintenance programs, Stonhard installed flooring, Legend Brands/RoofTec restoration services, Pure Air Control Services | | Warranty and extended programs | Embedded in pricing; generates deferred revenue | Current unearned revenue USD 75.3M and long-term unearned revenue USD 92.4M at FY2026 (standardized balance sheet) | | Licensing and royalties | Minor | The 10-K notes license fees and royalty income from numerous international license agreements, plus equity-method joint ventures | | Subscription | None identified | — | RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Customer types and end markets | End market | Segment exposure | Representative brands | |---|---|---| | Commercial / institutional building envelope (roofing, walls, waterproofing, sealants) | CPG | Tremco, Dryvit, Nudura, illbruck, Kalzip, Volteco | | Concrete, cement and infrastructure | CPG, PCG | Euclid, Toxement, Viapol, Prime Resins, Fibrecrete | | Industrial maintenance, oil and gas, petrochemical, power, data centres | PCG | Carboline, Stonhard, Fibergrate, Nullifire | | Food and pharma | PCG | Mantrose-Haeuser, NatureSeal, Profile Food Ingredients | | Marine, wood finishes, powder coatings | PCG | Pettit, Woolsey, FinishWorks/Mohawk, TCI | | Residential DIY and professional painters | Consumer | Rust-Oleum, Zinsser, Varathane, DAP | | Household cleaning | Consumer | The Pink Stuff, Krud Kutter, Mean Green | | Pigments, colorants, OEM and personal care | Consumer (Color Group) | Day-Glo | | Restoration services equipment | CPG (Legend Brands) | Dri-Eaz, Sapphire Scientific | ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
Company Headquarters: Amsterdam, Netherlands Founded: 1994 Workforce: ~35,200 Company Working: Akzo Nobel N.V. operates its business by manufacturing products of various industries such as decorative paints, automotive & specialty coatings, industrial coatings, powder coating and marine, protective and yacht coatings. The automotive and specialty coatings segment of the business comprises products such as aerospace coatings, consumer electronics coatings, automotive OEM coatings, vehicle refinishes and sign finishes. Further, its industrial coatings segment offers products including coil and extrusion coatings, wood finishes, packaging coatings, and adhesives. The company owns more than 3,100 patents and has robust research and development capabilities which is evident from the fact that it has spent around USD 1.33 billion on research and development in last five years and possess five R&D centers. The brand portfolio offered by the company includes Dulux, Sikkens, International and Interpon and has a strong geographical presence in around 150 countries.
Company Headquarters: Ohio, US Founded: 1866 Workforce: ~ 64,000 Company Working: Sherwin Williams Company specializes in the manufacturing of numerous types of paints and coatings products. The company makes its products available through a chain of over 5,000 stores which are operated by the company and through mass merchandisers, independent paint dealers, home centers, automotive retailers, hardware stores, and industrial distributors across various parts of North America, parts of Europe, China, Australia, and New Zealand. The company serves numerous industries such as transportation, construction, and packaging by offering a wide array of product under brands such as Miniwax, Purdy, Carbot and Krylon, among others. Also, it has around 136 manufacturing and distribution facilities across various geographical regions, further enabling the company to expand their market penetration.
58 interactive charts drawn from the Resorbable Polymer Market dataset — market size, each segment breakdown, and every region and country by segment. Open one to read its full data table and download it.
Global Resorbable Polymer Market By Region
Global Resorbable Polymer Market By Polymer Type
Global Resorbable Polymer Market By Application
Global Resorbable Polymer Market — North America by Country
Global Resorbable Polymer Market — North America by Application
Global Resorbable Polymer Market — North America by Polymer Type
Global Resorbable Polymer Market — U.S. by Application
Global Resorbable Polymer Market — U.S. by Polymer Type
Global Resorbable Polymer Market — Canada by Application
Global Resorbable Polymer Market — Canada by Polymer Type
Global Resorbable Polymer Market — Mexico by Application
Global Resorbable Polymer Market — Mexico by Polymer Type
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and forecast (2022–2032, USD Million)
Market Size (USD Million)
